$ALHC
Alignment Healthcare, Inc.

2021 Q2 Form 10-Q Financial Statement

#000095017021000261 Filed on May 17, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $309.0M $267.1M $224.6M
YoY Change 26.46% 18.9% 23.36%
Cost Of Revenue $274.4M $251.1M $193.4M
YoY Change 41.07% 29.83% 14.57%
Gross Profit $34.57M $15.99M $31.24M
YoY Change -30.61% -48.82% 134.86%
Gross Profit Margin 11.19% 5.99% 13.91%
Selling, General & Admin $71.15M $64.91M $32.79M
YoY Change 111.14% 97.99% 36.61%
% of Gross Profit 205.84% 406.04% 104.96%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $3.908M $3.737M $3.565M
YoY Change 10.83% 4.82% 1.86%
% of Gross Profit 11.31% 23.38% 11.41%
Operating Expenses $349.4M $319.7M $229.7M
YoY Change 50.8% 39.17% 738.5%
Operating Profit -$40.49M -$52.66M -$5.115M
YoY Change -421.7% 929.6% -63.72%
Interest Expense $4.329M $4.248M $4.160M
YoY Change 3.27% 2.12% -243.45%
% of Operating Profit
Other Income/Expense, Net -$4.270M -$4.210M -$4.957M
YoY Change 1.14% -15.07%
Pretax Income -$44.76M -$56.87M -$10.07M
YoY Change -635.11% 464.67% -41.1%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$44.76M -$56.87M -$10.07M
YoY Change -635.11% 464.67% -41.1%
Net Earnings / Revenue -14.49% -21.29% -4.48%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25 -$303.7K -$53.78K
COMMON SHARES
Basic Shares Outstanding 187.3M
Diluted Shares Outstanding 12.64M 0.000

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $494.6M $528.4M
YoY Change
Cash & Equivalents $494.6M $528.4M $192.4M
Short-Term Investments
Other Short-Term Assets $31.80M $26.77M
YoY Change
Inventory
Prepaid Expenses
Receivables $66.47M $49.46M
Other Receivables $0.00 $0.00
Total Short-Term Assets $592.9M $604.6M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $29.53M $28.40M
YoY Change
Goodwill $29.30M $29.30M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.447M $2.153M
YoY Change
Total Long-Term Assets $77.17M $74.70M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $592.9M $604.6M
Total Long-Term Assets $77.17M $74.70M
Total Assets $670.1M $679.3M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $136.5M $128.7M
YoY Change
Accrued Expenses $22.64M $21.48M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change
Total Short-Term Liabilities $173.7M $169.8M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $147.3M $145.7M
YoY Change
Other Long-Term Liabilities $8.607M $9.565M
YoY Change
Total Long-Term Liabilities $147.3M $145.7M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $173.7M $169.8M
Total Long-Term Liabilities $147.3M $145.7M
Total Liabilities $329.7M $325.1M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$481.2M -$436.4M
YoY Change
Common Stock $188.0K $188.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $340.4M $354.3M $42.33M
YoY Change
Total Liabilities & Shareholders Equity $670.1M $679.3M
YoY Change

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$44.76M -$56.87M -$10.07M
YoY Change -635.11% 464.67% -41.1%
Depreciation, Depletion And Amortization $3.908M $3.737M $3.565M
YoY Change 10.83% 4.82% 1.86%
Cash From Operating Activities -$23.45M -$38.11M -$21.82M
YoY Change 74.65%
INVESTING ACTIVITIES
Capital Expenditures -$6.421M -$4.446M
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$6.421M -$4.446M -$3.735M
YoY Change 19.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $390.6M $135.0M
YoY Change 189.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -3.529M 363.7M 131.5M
YoY Change 176.58%
NET CHANGE
Cash From Operating Activities -23.45M -38.11M -21.82M
Cash From Investing Activities -6.421M -4.446M -3.735M
Cash From Financing Activities -3.529M 363.7M 131.5M
Net Change In Cash -33.40M 321.1M 105.9M
YoY Change 203.13%
FREE CASH FLOW
Cash From Operating Activities -$23.45M -$38.11M -$21.82M
Capital Expenditures -$6.421M -$4.446M
Free Cash Flow -$17.03M -$33.66M
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Exercise In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExerciseInPeriodWeightedAverageRemainingContractualTerm
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm
CY2021Q1 alhc Finite Lived Intangible Asset Expected Amortization Thereafter
FiniteLivedIntangibleAssetExpectedAmortizationThereafter
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:FinancialServiceMember
CY2020 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:FinancialServiceMember
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001832466
CY2021Q1 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2023-06-30
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
CY2021Q1 dei Document Type
DocumentType
10-Q
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity File Number
EntityFileNumber
001-40295
CY2021Q1 dei Entity Registrant Name
EntityRegistrantName
ALIGNMENT HEALTHCARE, INC.
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5596242
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1100 W. Town and Country Road
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1600
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Orange
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92868
CY2021Q1 dei City Area Code
CityAreaCode
844
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
310-2247
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2021Q1 dei Trading Symbol
TradingSymbol
ALHC
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
187273782
CY2021Q1 us-gaap Cash
Cash
528417000
CY2020Q4 us-gaap Cash
Cash
207311000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
8000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
49458000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
40140000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26773000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
17225000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
604648000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
264676000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28403000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27145000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9577000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9888000
CY2021Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
34563000
CY2020Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
34645000
CY2021Q1 us-gaap Other Restricted Assets Noncurrent
OtherRestrictedAssetsNoncurrent
2153000
CY2020Q4 us-gaap Other Restricted Assets Noncurrent
OtherRestrictedAssetsNoncurrent
2148000
CY2021Q1 us-gaap Assets
Assets
679344000
CY2020Q4 us-gaap Assets
Assets
338502000
CY2021Q1 alhc Medical Expenses Payable Current
MedicalExpensesPayableCurrent
128673000
CY2020Q4 alhc Medical Expenses Payable Current
MedicalExpensesPayableCurrent
112605000
CY2021Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
19639000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
15675000
CY2021Q1 alhc Accrued Compensation
AccruedCompensation
21481000
CY2020Q4 alhc Accrued Compensation
AccruedCompensation
25172000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
169793000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
153452000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
145734000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
144168000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9565000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10271000
CY2021Q1 us-gaap Liabilities
Liabilities
325092000
CY2020Q4 us-gaap Liabilities
Liabilities
307891000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
164063787
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
187273782
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
187273782
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
164063787
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
164063787
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
188000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
164000
CY2021Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
790509000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
410018000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-436445000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-379571000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
354252000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30611000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
679344000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
338502000
CY2021Q1 us-gaap Premiums Earned Net
PremiumsEarnedNet
267000000
CY2020Q1 us-gaap Premiums Earned Net
PremiumsEarnedNet
224266000
CY2021Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
82000
CY2020Q1 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
367000
CY2021Q1 us-gaap Revenues
Revenues
267082000
CY2020Q1 us-gaap Revenues
Revenues
224633000
CY2021Q1 alhc Medical Expenses
MedicalExpenses
251095000
CY2020Q1 alhc Medical Expenses
MedicalExpenses
193396000
CY2021Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64914000
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
32787000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3737000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3565000
CY2021Q1 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted
154432027
CY2020Q1 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted
140764196
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
326000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
319746000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
229748000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-52664000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-5115000
CY2021Q1 us-gaap Interest Expense
InterestExpense
4248000
CY2020Q1 us-gaap Interest Expense
InterestExpense
4160000
CY2021Q1 alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
-38000
CY2020Q1 alhc Other Non Operating Expense Income
OtherNonOperatingExpenseIncome
797000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4210000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-4957000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-56874000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10072000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56874000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10072000
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-78711000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10072000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
131300000
CY2020Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
516000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
42327000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30611000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56874000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
361601000
CY2021Q1 alhc Stock Issued During Period Value To The Third Party Business Providers
StockIssuedDuringPeriodValueToTheThirdPartyBusinessProviders
6480000
CY2021Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
11510000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2398000
CY2021Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
1474000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
354252000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-56874000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-10072000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3789000
CY2020Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3670000
CY2021Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
550000
CY2020Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
540000
CY2021Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
1015000
CY2020Q1 us-gaap Paid In Kind Interest
PaidInKindInterest
982000
CY2021Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
CY2020Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-860000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9671000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
9547000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8908000
CY2021Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6000
CY2021Q1 alhc Share Based Compensation And Common Stock Payments
ShareBasedCompensationAndCommonStockPayments
20388000
CY2020Q1 alhc Share Based Compensation And Common Stock Payments
ShareBasedCompensationAndCommonStockPayments
326000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
648000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
573000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9326000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
131484000
CY2021Q1 alhc Proceeds From Acquisition Of Property And Equipment
ProceedsFromAcquisitionOfPropertyAndEquipment
-4446000
CY2020Q1 alhc Proceeds From Acquisition Of Property And Equipment
ProceedsFromAcquisitionOfPropertyAndEquipment
-3085000
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-2000
CY2021Q1 alhc Increase Decrease In Medical Expenses Payable
IncreaseDecreaseInMedicalExpensesPayable
16069000
CY2020Q1 alhc Increase Decrease In Medical Expenses Payable
IncreaseDecreaseInMedicalExpensesPayable
-5516000
CY2021Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-298000
CY2020Q1 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
6544000
CY2021Q1 alhc Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-3691000
CY2020Q1 alhc Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-1101000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
832000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
3883000
CY2021Q1 alhc Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
0
CY2020Q1 alhc Increase Decrease In Noncurrent Liabilities
IncreaseDecreaseInNoncurrentLiabilities
-3941000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38107000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21819000
CY2021Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
750000
CY2020Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1000000
CY2021Q1 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
750000
CY2020Q1 us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
250000
CY2021Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2020Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
100000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4446000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3735000
CY2021Q1 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
1474000
CY2020Q1 us-gaap Payments For Repurchase Of Equity
PaymentsForRepurchaseOfEquity
516000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
390600000
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
135000000
CY2021Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
25467000
CY2020Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3000000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
363659000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
321106000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
105930000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
207811000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86484000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528917000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192414000
CY2021Q1 us-gaap Interest Paid Net
InterestPaidNet
2682000
CY2020Q1 us-gaap Interest Paid Net
InterestPaidNet
2637000
CY2021Q1 alhc Acquisition Of Property In Accounts Payable
AcquisitionOfPropertyInAccountsPayable
474000
CY2020Q1 alhc Acquisition Of Property In Accounts Payable
AcquisitionOfPropertyInAccountsPayable
93000
CY2021Q1 alhc Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses
CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
3532000
CY2020Q1 alhc Common Stock Issuance Costs Included In Accounts Payable And Accrued Expenses
CommonStockIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
700000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
528417000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
192414000
CY2021Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
500000
CY2020Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
0
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
528917000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
192414000
CY2021Q1 alhc Number Of Consolidated Variable Interest Entities
NumberOfConsolidatedVariableInterestEntities
2
CY2021Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="padding-top:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="padding-top:6.0pt;text-indent:27.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the condensed consolidated financial statements requires management to make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements. Our significant estimates include, but are not limited to, the determination of medical expenses payable; the impact of risk adjustment provisions related to our Medicare contracts; collectability of receivables; right of use (“ROU”) assets and lease liabilities valuation; valuation of related impairment recognition of long-lived assets, including goodwill and intangible assets; equity-based compensation expense; and contingent liabilities. Estimates and judgments are based upon historical information and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates and the impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</span></p>
CY2021Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
267000000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
224266000
CY2021Q1 alhc Schedule Of Property And Equipment Estimated Useful Lives Table Textblock
ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextblock
<p style="padding-top:6.0pt;text-indent:27.35pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense is computed using the straight-line method generally based on the following estimated useful lives:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:72.303%;"/> <td style="width:1.556%;"/> <td style="width:26.141%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Estimated Service Lives (years)</span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer and equipment</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office equipment and furniture</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-</span><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 (or lease term, if shorter)</span></span></p></td> </tr> </table>
CY2021Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="padding-top:18.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span></p><p style="padding-top:6.0pt;text-indent:27.35pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash deposits and restricted investments with financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to certain limits. At March 31, 2021 and December 31, 2020, there was $</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">525,983 </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and $</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205,882</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively in excess of FDIC-insured limits.</span></p>
CY2021Q1 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
525983000
CY2020 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
205882000
CY2020Q1 us-gaap Income Tax Reconciliation Nondeductible Expense Life Insurance
IncomeTaxReconciliationNondeductibleExpenseLifeInsurance
3343000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P4Y
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-56874000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10072000
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
165611120
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
152916985
CY2021Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
11179093
CY2020Q1 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
12152789
CY2021Q1 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted
154432027
CY2020Q1 alhc Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic And Diluted
WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasicAndDiluted
140764196
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12640391
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
0
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1441000
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
1440000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
145734000
CY2021Q1 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
150754000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
144168000
CY2020Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
149965000
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2021Q1 us-gaap Government Contract Receivable
GovernmentContractReceivable
18828000
CY2020Q4 us-gaap Government Contract Receivable
GovernmentContractReceivable
10392000
CY2021Q1 alhc Pharmacy Rebates
PharmacyRebates
-28512000
CY2020Q4 alhc Pharmacy Rebates
PharmacyRebates
-25888000
CY2021Q1 us-gaap Other Receivables
OtherReceivables
2126000
CY2020Q4 us-gaap Other Receivables
OtherReceivables
3860000
CY2021Q1 us-gaap Accounts Receivable Gross
AccountsReceivableGross
49466000
CY2020Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
40140000
CY2021Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
8000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2021Q1 us-gaap Accounts Receivable Net
AccountsReceivableNet
49458000
CY2020Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
40140000
CY2021Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8000
CY2020Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
10000
CY2021Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
104772000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
99852000
CY2021Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
76369000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
72707000
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28403000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
27145000
CY2021Q1 us-gaap Depreciation
Depreciation
3707000
CY2020Q1 us-gaap Depreciation
Depreciation
3588000
CY2021Q1 us-gaap Goodwill Gross
GoodwillGross
29303000
CY2021Q1 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2021Q1 us-gaap Goodwill
Goodwill
29303000
CY2021Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
37136000
CY2021Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2573000
CY2021Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
34563000
CY2020Q4 us-gaap Goodwill Gross
GoodwillGross
29303000
CY2020Q4 us-gaap Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
0
CY2020Q4 us-gaap Goodwill
Goodwill
29303000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
37136000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2491000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
34645000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
82000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
82000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
245000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
327000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
166000
CY2021Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
22000
CY2021Q1 alhc Estimated Amortization Expense Related To Intangible Assets
EstimatedAmortizationExpenseRelatedToIntangibleAssets
760000
CY2021Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2020Q1 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2021Q1 us-gaap Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense
ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
<p style="padding-top:6.0pt;text-indent:27.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table is a detail of medical expenses payable at March 31, 2021 and December 31, 2020:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.892%;"/> <td style="width:1.657%;"/> <td style="width:1.037%;"/> <td style="width:12.86%;"/> <td style="width:1.0%;"/> <td style="width:1.657%;"/> <td style="width:1.037%;"/> <td style="width:12.86%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:8.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">March 31,<br/>2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,<br/>2020</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Claims incurred but not paid</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,337</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82,391</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Capitation payable, risk-sharing payable, and other</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47,336</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,214</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,673</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">112,605</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span> </span></p></td> </tr> </table>
CY2021Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
81337000
CY2020Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
82391000
CY2021Q1 alhc Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other
LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther
47336000
CY2020Q4 alhc Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other
LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther
30214000
CY2021Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
128673000
CY2020Q4 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
112605000
CY2021Q1 alhc Remaining Claim Amounts Payment Period
RemainingClaimAmountsPaymentPeriod
P3Y
CY2020Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
82391000
CY2019Q4 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
83939000
CY2021Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
83223000
CY2020Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
70693000
CY2021Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-3745000
CY2020Q1 us-gaap Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense
SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
-7078000
CY2021Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
79478000
CY2020Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
63615000
CY2021Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
22746000
CY2020Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
25825000
CY2021Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
57786000
CY2020Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
49547000
CY2021Q1 us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
80532000
CY2020Q1 us-gaap Payments For Losses And Loss Adjustment Expense
PaymentsForLossesAndLossAdjustmentExpense
75372000
CY2021Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
81337000
CY2020Q1 us-gaap Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount
LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
72182000
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q1 alhc Liability For Claims And Claims Other Medical Expenses Payable
LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable
47336000
CY2020Q1 alhc Liability For Claims And Claims Other Medical Expenses Payable
LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable
28447000
CY2021Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
128673000
CY2020Q1 us-gaap Liability For Claims And Claims Adjustment Expense
LiabilityForClaimsAndClaimsAdjustmentExpense
100629000
CY2021Q1 alhc Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense
ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense
400000
CY2021Q1 alhc Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense
ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense
400000
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
150931000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
149915000
CY2021Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5197000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
5747000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
145734000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
144168000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
145734000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
144168000
CY2021Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
150931000
CY2021Q1 alhc Debt Instrument Principal Balance Outstanding
DebtInstrumentPrincipalBalanceOutstanding
135000000
CY2021Q1 alhc Long Term Debt Commitment Fee
LongTermDebtCommitmentFee
6750000
CY2021Q1 alhc Debt Instrument Payment In Kind Interest On Principal Balance
DebtInstrumentPaymentInKindInterestOnPrincipalBalance
9035000
CY2021Q1 alhc Debt Instrument Payment In Kind Interest On Principal Balance Commitment Fee
DebtInstrumentPaymentInKindInterestOnPrincipalBalanceCommitmentFee
146000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11123391
CY2021Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.00
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue
0
CY2021Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodIntrinsicValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11123391
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.00
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y11M26D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
43715000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2021Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
83982000
CY2020Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
0
CY2020Q1 alhc Share Based Compensation Arrangement By Share Based Payment Award Options Redeemed In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsRedeemedInPeriodWeightedAverageGrantDateFairValue
0
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31787000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
326000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
31787000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
326000
CY2021Q1 alhc Description Of Tangible Net Equity Requirement
DescriptionOfTangibleNetEquityRequirement
The required amount is the larger of: (1) $1,000; (2) 2% of the first $150,000 of annualized premium revenue, plus 1% of annualized premium revenue in excess of $150,000; or (3) 8% of the first $150,000 of annualized health care expenditures, except for those paid on a capitated or managed hospital payment basis, plus 4% of the annualized health care expenditures in excess of $150,000, except those paid on a capitated or managed hospital payment basis, plus 4% of annualized hospital expenditures paid on a managed hospital payment basis. We were in compliance with the TNE requirement at for all periods presented.
CY2021Q1 alhc Tangible Net Equity Required Amount
TangibleNetEquityRequiredAmount
1000000
CY2021Q1 alhc Annualized Premium Revenue Percentage
AnnualizedPremiumRevenuePercentage
0.02
CY2021Q1 us-gaap Tangible Capital Required For Capital Adequacy
TangibleCapitalRequiredForCapitalAdequacy
150000000
CY2021Q1 alhc Annualized Premium Revenue Excess Amount Percentage
AnnualizedPremiumRevenueExcessAmountPercentage
0.01
CY2021Q1 alhc Annualized Health Care Expenditures Percentage
AnnualizedHealthCareExpendituresPercentage
0.08
CY2021Q1 alhc Annualized Health Care Expenditures Excess Amount Percentage
AnnualizedHealthCareExpendituresExcessAmountPercentage
0.04
CY2021Q1 alhc Annualized Hospital Expenditure Paid Percentage
AnnualizedHospitalExpenditurePaidPercentage
0.04
CY2021Q1 alhc Amounts Accrued For Legal Proceedings
AmountsAccruedForLegalProceedings
0
CY2020Q4 alhc Amounts Accrued For Legal Proceedings
AmountsAccruedForLegalProceedings
0

Files In Submission

Name View Source Status
0000950170-21-000261-index-headers.html Edgar Link pending
0000950170-21-000261-index.html Edgar Link pending
0000950170-21-000261.txt Edgar Link pending
0000950170-21-000261-xbrl.zip Edgar Link pending
alhc-20210331-ex10_10.htm Edgar Link pending
alhc-20210331-ex10_11.htm Edgar Link pending
alhc-20210331-ex10_9.htm Edgar Link pending
alhc-20210331-ex31_1.htm Edgar Link pending
alhc-20210331-ex31_2.htm Edgar Link pending
alhc-20210331-ex32_1.htm Edgar Link pending
alhc-20210331-ex32_2.htm Edgar Link pending
alhc-20210331.htm Edgar Link pending
alhc-20210331.xsd Edgar Link pending
alhc-20210331_cal.xml Edgar Link unprocessable
alhc-20210331_def.xml Edgar Link unprocessable
alhc-20210331_htm.xml Edgar Link completed
alhc-20210331_lab.xml Edgar Link unprocessable
alhc-20210331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending